ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

CRVS Corvus Pharmaceuticals Inc

4.81
-0.28 (-5.50%)
Pre Market
Last Updated: 11:10:56
Delayed by 15 minutes
Share Name Share Symbol Market Type
Corvus Pharmaceuticals Inc NASDAQ:CRVS NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.28 -5.50% 4.81 4.75 5.09 434 11:10:56

Corvus Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

03/09/2024 9:05pm

GlobeNewswire Inc.


Corvus Pharmaceuticals (NASDAQ:CRVS)
Historical Stock Chart


From Jun 2024 to Dec 2024

Click Here for more Corvus Pharmaceuticals Charts.

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that Richard A. Miller, M.D., president and chief executive officer, and Jeffrey Arcara, chief business officer, will conduct one-on-one meetings with investors and present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference, which is being held in New York from September 9-11, 2024. The Company’s presentation will be on Tuesday, September 10 at 12:00pm ET.

A webcast of the presentation will be available live and for 90 days following the event. The webcast may be accessed via the investor relations section of the Corvus website.

About Corvus PharmaceuticalsCorvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com.

INVESTOR CONTACT:Leiv LeaChief Financial OfficerCorvus Pharmaceuticals, Inc.+1-650-900-4522llea@corvuspharma.com

MEDIA CONTACT:Sheryl SeapyReal Chemistry+1-949-903-4750sseapy@realchemistry.com

1 Year Corvus Pharmaceuticals Chart

1 Year Corvus Pharmaceuticals Chart

1 Month Corvus Pharmaceuticals Chart

1 Month Corvus Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock